Pathogenesis of choriocarcinoma: clinical, genetic and stem cell perspectives

Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interest

Bibliography

• 1  Nogales FF: Germ cell tumors of the ovary. In: Haines & Tailor Obstetrical and Gynecological Pathology. Fox H, Wells M (Eds). Churchill Livingstone, Edinburgh, UK, 771–820 (2003).
  Google Scholar
• 2  Pattillo RA: Gestational and non-gestational trophoblastic neoplasms: new developments in DNA analysis, metabolic function, diagnosis and treatment. Curr. Opin. Obstet. Gynecol.5,486–489 (1993).▪ Interesting early report that describes the molecular biological characteristics of gestational and nongestational trophoblastic neoplasm.
  Medline CASGoogle Scholar
• 3  Talerman A: Germ cell tumors of the ovary. In: Blaustein’s Pathology of the Female Genital Tract. Kurman RJ (Ed.). Springer-Verlag, New York, NY, USA, 967–1033 (2002).
  Google Scholar
• 4  Chen F, Tatsumi A, Numoto S: Combined choriocarcinoma and adenocarcinoma of the lung occurring in a man: case report and review of the literature. Cancer91,123–129 (2001).
  Medline CASGoogle Scholar
• 5  Ikura Y, Inoue T, Tsukuda H, Yamamoto T, Ueda M, Kobayashi Y: Primary choriocarcinoma and human chorionic gonadotrophin-producing giant cell carcinoma of the lung: are they independent entities? Histopathology36,17–25 (2000).
  Medline CASGoogle Scholar
• 6  Verbeek W, Schulten HJ, Sperling M et al.: Rectal adenocarcinoma with choriocarcinomatous differentiation: clinical and genetic aspects. Hum. Pathol.35,1427–1430 (2004).
  Medline CASGoogle Scholar
• 7  Arima T, Imamura T, Sakuragi N et al.: Malignant trophoblastic neoplasms with different modes of origin. Cancer Genet. Cytogenet.85,5–15 (1995).
  Medline CASGoogle Scholar
• 8  Tsujioka H, Hamada H, Miyakawa T, Hachisuga T, Kawarabayashi T: A pure nongestational choriocarcinoma of the ovary diagnosed with DNA polymorphism analysis. Gynecol. Oncol.89,540–542 (2003).
  MedlineGoogle Scholar
• 9  Yamamoto E, Ino K, Yamamoto T et al.: A pure nongestational choriocarcinoma of the ovary diagnosed with short tandem repeat analysis: case report and review of the literature. Int. J. Gynecol. Cancer.17,254–258 (2007).
  Medline CASGoogle Scholar
• 10  Fisher RA, Savage PM, MacDermott C et al.: The impact of molecular genetic diagnosis on the management of women with hCG-producing malignancies. Gynecol. Oncol.107,413–419 (2007).▪▪ Highlights the clinical significance of analysis of the genetic origin of atypical hCG-producing tumors in women using the technique fluorescent microsatellite genotyping.
  Medline CASGoogle Scholar
• 11  Genest DR, Berkowitz RS, Fisher RA: Gestational Trophoblastic Disease. IARC, Lyon, France (2003).
  Google Scholar
• 12  Shih Ie M: Gestational trophoblastic neoplasia – pathogenesis and potential therapeutic targets. Lancet Oncol.8,642–650 (2007).▪ Summarizes the recent advances in molecular etiology of gestational trophoblastic neoplasia and highlights those molecules that can be possible targets for therapy.
  MedlineGoogle Scholar
• 13  Altieri A, Franceschi S, Ferlay J, Smith J, La Vecchia C: Epidemiology and aetiology of gestational trophoblastic diseases. Lancet Oncol.4,670–678 (2003).
  MedlineGoogle Scholar
• 14  Seckl MJ, Fisher RA, Salerno G et al.: Choriocarcinoma and partial hydatidiform moles. Lancet356,36–39 (2000).
  Medline CASGoogle Scholar
• 15  Lok CA, Ansink AC, Grootfaam D, van der Velden J, Verheijen RH, ten Kate-Booij MJ: Treatment and prognosis of post term choriocarcinoma in The Netherlands. Gynecol. Oncol.103,698–702 (2006).
  MedlineGoogle Scholar
• 16  Li HW, Tsao SW, Cheung AN: Current understandings of the molecular genetics of gestational trophoblastic diseases. Placenta23,20–31 (2002).
  MedlineGoogle Scholar
• 17  Ahmed MN, Kim K, Haddad B, Berchuck A, Qumsiyeh MB: Comparative genomic hybridization studies in hydatidiform moles and choriocarcinoma: amplification of 7q21–q31 and loss of 8p12–p21 in choriocarcinoma. Cancer Genet. Cytogenet.116,10–15 (2000).
  Medline CASGoogle Scholar
• 18  Ishiwata I, Ishiwata C, Tsuiki A, Kiguchi K, Hashimoto H, Ishikawa H: Establishment and characterization of a human gestational choriocarcinoma cell line (HOCC). Hum. Cell17,33–41 (2004).
  MedlineGoogle Scholar
• 19  Rodriguez E, Melamed J, Reuter V, Chaganti RS: Chromosomal abnormalities in choriocarcinomas of the female. Cancer Genet. Cytogenet.80,9–12 (1995).
  Medline CASGoogle Scholar
• 20  Surti U, Habibian R: Chromosomal rearrangement in choriocarcinoma cell lines. Cancer Genet. Cytogenet.38,229–240 (1989).
  Medline CASGoogle Scholar
• 21  Matsuda T, Sasaki M, Kato H et al.: Human chromosome 7 carries a putative tumor suppressor gene(s) involved in choriocarcinoma. Oncogene15,2773–2781 (1997).▪ Uses the microcell hybrids approach to test the effect of individual chromosome on tumorigenicity of choriocarcinoma cells. Significant effect was found with chromosome 7, but not a few other chromosomes, and the results suggest that chromosome 7 contains a putative tumor suppressor gene(s) for choriocarcinoma.
  Medline CASGoogle Scholar
• 22  Burke B, Sebire NJ, Moss J et al.: Evaluation of deletions in 7q11.2 and 8p12–p21 as prognostic indicators of tumor development following molar pregnancy. Gynecol. Oncol.103,642–648 (2006).
  Medline CASGoogle Scholar
• 23  Pils D, Horak P, Gleiss A et al.: Five genes from chromosomal band 8p22 are significantly down-regulated in ovarian carcinoma: N33 and EFA6R have a potential impact on overall survival. Cancer104,2417–2429 (2005).
  Medline CASGoogle Scholar
• 24  Cheung AN: Gestational trophoblastic disease. In: Pathology of the Female Reproductive Tract. Robboy S, Russel P, Mutter G (Eds). Churchill Livingstone. 881–907 (2008).
  Google Scholar
• 25  Arima T, Matsuda T, Takagi N, Wake N: Association of IGF2 and H19 imprinting with choriocarcinoma development. Cancer Genet. Cytogenet.93,39–47 (1997).
  Medline CASGoogle Scholar
• 26  Cheung AN, Shen DH, Khoo US, Wong LC, Ngan HY: p21WAF1/CIP1 expression in gestational trophoblastic disease: correlation with clinicopathological parameters, and Ki67 and p53 gene expression. J. Clin. Pathol.51,159–162 (1998).
  Medline CASGoogle Scholar
• 27  Fulop V, Mok SC, Genest DR, Gati I, Doszpod J, Berkowitz RS: p53, p21, Rb and mdm2 oncoproteins. Expression in normal placenta, partial and complete mole, and choriocarcinoma. J. Reprod. Med.43,119–127 (1998).
  Medline CASGoogle Scholar
• 28  Fulop V, Colitti CV, Genest D et al.: DOC-2/hDab2, a candidate tumor suppressor gene involved in the development of gestational trophoblastic diseases. Oncogene17,419–424 (1998).
  Medline CASGoogle Scholar
• 29  Li HW, Leung SW, Cheung AN, Yu MM, Chan LK, Wong YF: Expression of maspin in gestational trophoblastic disease. Gynecol. Oncol.101,76–81 (2006).
  Medline CASGoogle Scholar
• 30  Asanoma K, Kato H, Inoue T, Matsuda T, Wake N: Analysis of a candidate gene associated with growth suppression of choriocarcinoma and differentiation of trophoblasts. J. Reprod. Med.49,617–626 (2004).
  Medline CASGoogle Scholar
• 31  Fong PY, Xue WC, Ngan HY et al.: Caspase activity is downregulated in choriocarcinoma: a cDNA array differential expression study. J. Clin. Pathol.59,179–183 (2006).
  Medline CASGoogle Scholar
• 32  Feng HC, Tsao SW, Ngan HY et al.: Differential gene expression identified in complete hydatidiform mole by combining suppression subtractive hybridization and cDNA microarray. Placenta27,521–526 (2006).
  Medline CASGoogle Scholar
• 33  Feng H, Cheung AN, Xue WC et al.: Down-regulation and promoter methylation of tissue inhibitor of metalloproteinase 3 in choriocarcinoma. Gynecol. Oncol.94,375–382 (2004).
  Medline CASGoogle Scholar
• 34  Xue WC, Chan KY, Feng HC et al.: Promoter hypermethylation of multiple genes in hydatidiform mole and choriocarcinoma. J. Mol. Diagn.6,326–334 (2004).▪ Reports the frequent hypermethylation of a panel of tumor suppressor genes in choriocarcinoma and hydatidiform moles that develop gestational trophoblastic neoplasia.
  Medline CASGoogle Scholar
• 35  Chiu RW, Chim SS, Wong IH et al.: Hypermethylation of RASSF1A in human and rhesus placentas. Am. J. Pathol.170,941–950 (2007).
  Medline CASGoogle Scholar
• 36  Shih IM, Kurman RJ: Expression of melanoma cell adhesion molecule in intermediate trophoblast. Lab. Invest.75,377–388 (1996).
  Medline CASGoogle Scholar
• 37  Singer G, Kurman RJ, McMaster MT, Shih Ie M: HLA-G immunoreactivity is specific for intermediate trophoblast in gestational trophoblastic disease and can serve as a useful marker in differential diagnosis. Am. J. Surg. Pathol.26,914–920 (2002).
  MedlineGoogle Scholar
• 38  Shih Ie M, Kuo KT: Power of the eternal youth: nanog expression in the gestational choriocarcinoma. Am. J. Pathol.173,911–914 (2008).
  MedlineGoogle Scholar
• 39  Asanoma K, Matsuda T, Kondo H et al.: NECC1, a candidate choriocarcinoma suppressor gene that encodes a homeodomain consensus motif. Genomics81,15–25 (2003).
  Medline CASGoogle Scholar
• 40  Asanoma K, Kato H, Yamaguchi S et al.: HOP/NECC1, a novel regulator of mouse trophoblast differentiation. J. Biol. Chem.282,24065–24074 (2007).
  Medline CASGoogle Scholar
• 41  Fulop V, Mok SC, Genest DR, Szigetvari I, Cseh I, Berkowitz RS: c-myc, c-erbB-2, c-fms and bcl-2 oncoproteins. Expression in normal placenta, partial and complete mole, and choriocarcinoma. J. Reprod. Med.43,101–110 (1998).
  Medline CASGoogle Scholar
• 42  Tuncer ZS, Vegh GL, Fulop V, Genest DR, Mok SC, Berkowitz RS: Expression of epidermal growth factor receptor-related family products in gestational trophoblastic diseases and normal placenta and its relationship with development of postmolar tumor. Gynecol. Oncol.77,389–393 (2000).
  Medline CASGoogle Scholar
• 43  Coan PM, Burton GJ, Ferguson-Smith AC: Imprinted genes in the placenta – a review. Placenta26(Suppl. A),S10–S20 (2005).
  MedlineGoogle Scholar
• 44  Wilkins JF, Haig D: What good is genomic imprinting: the function of parent-specific gene expression. Nat. Rev. Genet.4,359–368 (2003).▪▪ Provides a comprehensive appraisal on the hypotheses that attempt to explain the advantage of genomic imprinting. The balance between expression of maternal and paternal alleles is also discussed.
  Medline CASGoogle Scholar
• 45  Fisher RA, Hodges MD: Genomic imprinting in gestational trophoblastic disease-– a review. Placenta24(Suppl. A),S111–S118 (2003).▪ Good review of studies on the involvement of imprinting genes in gestational trophoblastic disease (GTD), which is applied for understanding of the function of genomic imprinting in early development.
  MedlineGoogle Scholar
• 46  Tycko B: Imprinted genes in placental growth and obstetric disorders. Cytogenet. Genome. Res.113,271–278 (2006).
  Medline CASGoogle Scholar
• 47  Chilosi M, Piazzola E, Lestani M et al.: Differential expression of p57kip2, a maternally imprinted cdk inhibitor, in normal human placenta and gestational trophoblastic disease. Lab. Invest.78,269–276 (1998).
  Medline CASGoogle Scholar
• 48  Chan HY, Siu MK, Zhang HJ et al.: Activated Stat3 expression in gestational trophoblastic disease: correlation with clinicopathological parameters and apoptotic indices. Histopathology53,139–146 (2008).
  Medline CASGoogle Scholar
• 49  Li AS, Siu MK, Zhang H et al.: Hypermethylation of SOX2 gene in hydatidiform mole and choriocarcinoma. Reprod. Sci.15,735–744 (2008).
  Medline CASGoogle Scholar
• 50  Siu MK, Wong ES, Chan HY, Ngan HY, Chan KY, Cheung AN: Overexpression of NANOG in gestational trophoblastic diseases: effect on apoptosis, cell invasion, and clinical outcome. Am. J. Pathol.173,1165–1172 (2008).▪▪ Interesting study on the role of NANOG, an important stem cell transcription factor in GTD. It is found that NANOG is involved in the pathogenesis and clinical progress of GTD and affects apoptosis, cell migration and invasion.
  Medline CASGoogle Scholar
• 51  Zhang HJ, Siu MK, Wong ES et al.: Oct4 is epigenetically regulated by methylation in normal placenta and gestational trophoblastic disease. Placenta29,549–554 (2008).
  Medline CASGoogle Scholar
• 52  Mao TL, Kurman RJ, Huang CC, Lin MC, Shih Ie M: Immunohistochemistry of choriocarcinoma: an aid in differential diagnosis and in elucidating pathogenesis. Am. J. Surg. Pathol.31,1726–1732 (2007).
  MedlineGoogle Scholar
• 53  Zhang HJ, Xue WC, Siu MK, Liao XY, Ngan HY, Cheung AN: P63 expression in gestational trophoblastic disease: correlation with proliferation and apoptotic dynamics. Int. J. Gynecol. Pathol. (2008) (in press).
  MedlineGoogle Scholar
• 54  Shih IM, Kurman RJ: p63 expression is useful in the distinction of epithelioid trophoblastic and placental site trophoblastic tumors by profiling trophoblastic subpopulations. Am. J. Surg. Pathol.28,1177–1183 (2004).
  MedlineGoogle Scholar
• 55  Li HW, Cheung AN, Tsao SW, Cheung AL, O WS: Expression of e-cadherin and beta-catenin in trophoblastic tissue in normal and pathological pregnancies. Int. J. Gynecol. Pathol.22,63–70 (2003).
  MedlineGoogle Scholar
• 56  Roth LM, Talerman A: Recent advances in the pathology and classification of ovarian germ cell tumors. Int. J. Gynecol. Pathol.25,305–320 (2006).
  MedlineGoogle Scholar
• 57  Ulbright TM: Germ cell tumors of the gonads: a selective review emphasizing problems in differential diagnosis, newly appreciated, and controversial issues. Mod. Pathol.18(Suppl. 2),S61–S79 (2005).
  MedlineGoogle Scholar
• 58  Ulbright TM, Amin MB, Young RH (Eds): Tumors of the testis, adnexa, spermatic cord and csrotum. In: Atlas of Tumor Pathology. Volume 3, Armed Forces Institute of pathology, Washington DC, USA (1999).
  Google Scholar
• 59  Chaganti RS, Rodriguez E, Mathew S: Origin of adult male mediastinal germ-cell tumors. Lancet343,1130–1132 (1994).
  Medline CASGoogle Scholar
• 60  Moran CA, Suster S: Primary mediastinal choriocarcinomas: a clinicopathologic and immunohistochemical study of eight cases. Am. J. Surg. Pathol.21,1007–1012 (1997).
  Medline CASGoogle Scholar
• 61  Lind GE, Skotheim RI, Lothe RA: The epigenome of testicular germ cell tumors. Apmis.115,1147–1160 (2007).▪▪ Discusses the change in DNA methylation status of germ cells during embryological development as compared with degree of differentiation in different types of germ cell tumors.
  Medline CASGoogle Scholar
• 62  Manton KJ, Douglas ML, Netzel-Arnett S et al.: Hypermethylation of the 5´ CpG island of the gene encoding the serine protease Testisin promotes its loss in testicular tumorigenesis. Br. J. Cancer92,760–769 (2005).
  Medline CASGoogle Scholar
• 63  Honorio S, Agathanggelou A, Wernert N, Rothe M, Maher ER, Latif F: Frequent epigenetic inactivation of the RASSF1A tumor suppressor gene in testicular tumors and distinct methylation profiles of seminoma and nonseminoma testicular germ cell tumors. Oncogene22,461–466 (2003).
  Medline CASGoogle Scholar
• 64  Korkola JE, Houldsworth J, Chadalavada RS et al.: Down-regulation of stem cell genes, including those in a 200-kb gene cluster at 12p13.31, is associated with in vivo differentiation of human male germ cell tumors. Cancer Res.66,820–827 (2006).
  Medline CASGoogle Scholar
• 65  Skotheim RI, Lind GE, Monni O et al.: Differentiation of human embryonal carcinomas in vitro and in vivo reveals expression profiles relevant to normal development. Cancer Res.65,5588–5598 (2005).
  Medline CASGoogle Scholar
• 66  Korkola JE, Houldsworth J, Dobrzynski D et al.: Gene expression-based classification of nonseminomatous male germ cell tumors. Oncogene24,5101–5107 (2005).
  Medline CASGoogle Scholar
• 67  Santagata S, Ligon KL, Hornick JL: Embryonic stem cell transcription factor signatures in the diagnosis of primary and metastatic germ cell tumors. Am. J. Surg. Pathol.31,836–845 (2007).▪ Reports the expression profile of the stem cell transcription factors in the different types of testicular germ cell tumors.
  MedlineGoogle Scholar
• 68  Hoei-Hansen CE: Application of stem cell markers in search for neoplastic germ cells in dysgenetic gonads, extragonadal tumors, and in semen of infertile men. Cancer Treat. Rev.34,348–367 (2008).
  Medline CASGoogle Scholar
• 69  Clark AT: The stem cell identity of testicular cancer. Stem Cell Rev.3,49–59 (2007).▪ Discusses the possible relationship between normal germ cell, cancer stem cell and germ cell tumorigenesis.
  Medline CASGoogle Scholar
• 70  Samaniego F, Rodriguez E, Houldsworth J et al.: Cytogenetic and molecular analysis of human male germ cell tumors: chromosome 12 abnormalities and gene amplification. Genes Chromosomes Cancer1,289–300 (1990).
  Medline CASGoogle Scholar
• 71  Ben-Porath I, Thomson MW, Carey VJ et al.: An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat. Genet.40,499–507 (2008).
  Medline CASGoogle Scholar
• 72  Stoop H, Honecker F, van de Geijn GJ et al.: Stem cell factor as a novel diagnostic marker for early malignant germ cells. J. Pathol.216,43–54 (2008).
  Medline CASGoogle Scholar
• 73  Yakeishi Y, Mori M, Enjoji M: Distribution of β-human chorionic gonadotropin-positive cells in noncancerous gastric mucosa and in malignant gastric tumors. Cancer66,695–701 (1990).
  Medline CASGoogle Scholar
• 74  Campo E, Palacin A, Benasco C, Quesada E, Cardesa A: Human chorionic gonadotropin in colorectal carcinoma. An immunohistochemical study. Cancer59,1611–1616 (1987).
  Medline CASGoogle Scholar
• 75  Liu AY, Chan WY, Ng EK et al.: Gastric choriocarcinoma shows characteristics of adenocarcinoma and gestational choriocarcinoma: a comparative genomic hybridization and fluorescence in situ hybridization study. Diagn. Mol. Pathol.10,161–165 (2001).
  Medline CASGoogle Scholar
• 76  Bradley CS, Benjamin I, Wheeler JE, Rubin SC: Endometrial adenocarcinoma with trophoblastic differentiation. Gynecol. Oncol.69,74–77 (1998).
  Medline CASGoogle Scholar
• 77  Horn LC, Hanel C, Bartholdt E, Dietel J: Mixed serous carcinoma of the endometrium with trophoblastic differentiation: analysis of the p53 tumor suppressor gene suggests stem cell origin. Ann. Diagn. Pathol.12,1–3 (2008).▪ Demonstrates genetic evidence supportive of multidirectional development of adenocarcinoma and choriocarcinoma from common stem cells in the endometrium.
  MedlineGoogle Scholar
• 78  Wicha MS, Liu S, Dontu G: Cancer stem cells: an old idea – a paradigm shift. Cancer Res.66,1883–1890; discussion 1895–1896 (2006).
  Medline CASGoogle Scholar
• 79  Cheung AN, Srivastava G, Chung LP et al.: Expression of the p53 gene in trophoblastic cells in hydatidiform moles and normal human placentas. J. Reprod. Med.39,223–227 (1994).
  Medline CASGoogle Scholar
• 80  Qiao S, Nagasaka T, Harada T, Nakashima N: p53, Bax and Bcl-2 expression, and apoptosis in gestational trophoblast of complete hydatidiform mole. Placenta19,361–369 (1998).
  Medline CASGoogle Scholar
• 81  Cameron B, Gown AM, Tamimi HK: Expression of c-erb B-2 oncogene product in persistent gestational trophoblastic disease. Am. J. Obstet. Gynecol.170,1616–1621; discussion 1621–1622 (1994).
  Medline CASGoogle Scholar
• 82  Yazaki-Sun S, Daher S, de Souza Ishigai MM, Alves MT, Mantovani TM, Mattar R: Correlation of c-erbB-2 oncogene and p53 tumor suppressor gene with malignant transformation of hydatidiform mole. J. Obstet. Gynaecol. Res.32,265–272 (2006).
  MedlineGoogle Scholar
• 83  Kim YT, Cho NH, Ko JH et al.: Expression of cyclin E in placentas with hydropic change and gestational trophoblastic diseases: implications for the malignant transformation of trophoblasts. Cancer89,673–679 (2000).
  Medline CASGoogle Scholar
• 84  Olvera M, Harris S, Amezcua CA et al.: Immunohistochemical expression of cell cycle proteins E2F-1, Cdk-2, Cyclin E, p27(kip1), and Ki-67 in normal placenta and gestational trophoblastic disease. Mod. Pathol.14,1036–1042 (2001).
  Medline CASGoogle Scholar
• 85  Amezcua CA, Bahador A, Naidu YM, Felix JC: Expression of human telomerase reverse transcriptase, the catalytic subunit of telomerase, is associated with the development of persistent disease in complete hydatidiform moles. Am. J. Obstet. Gynecol.184,1441–1446 (2001).
  Medline CASGoogle Scholar
• 86  Cheung AN, Zhang DK, Liu Y, Ngan HY, Shen DH, Tsao SW: Telomerase activity in gestational trophoblastic disease. J. Clin. Pathol.52,588–592 (1999).▪ One of the first few reports on clinical significance of high telomerase activity in hydatidiform mole. High telomerase activity in choriocarcinoma is also reported.
  Medline CASGoogle Scholar
• 87  Chiu PM, Ngan YS, Khoo US, Cheung AN: Apoptotic activity in gestational trophoblastic disease correlates with clinical outcome: assessment by the caspase-related M30 CytoDeath antibody. Histopathology38,243–249 (2001).
  Medline CASGoogle Scholar
• 88  Wong SY, Ngan HY, Chan CC, Cheung AN: Apoptosis in gestational trophoblastic disease is correlated with clinical outcome and Bcl-2 expression but not Bax expression. Mod. Pathol.12,1025–1033 (1999).▪ One of the first few reports on clinical significance of apoptotic activity in hydatidiform mole.
  Medline CASGoogle Scholar
• 89  Shih IM, Kurman RJ: Ki-67 labeling index in the differential diagnosis of exaggerated placental site, placental site trophoblastic tumor, and choriocarcinoma: a double immunohistochemical staining technique using Ki-67 and Mel-CAM antibodies. Hum. Pathol.29,27–33 (1998).
  Medline CASGoogle Scholar
• 90  Xue WC, Khoo US, Ngan HY et al.: Minichromosome maintenance protein 7 expression in gestational trophoblastic disease: correlation with Ki67, PCNA and clinicopathological parameters. Histopathology43,485–490 (2003).
  Medline CASGoogle Scholar
• 91  Xue WC, Feng HC, Chan KY et al.: Id helix-loop-helix proteins are differentially expressed in gestational trophoblastic disease. Histopathology47,303–309 (2005).
  Medline CASGoogle Scholar
• 92  Petignat P, Laurini R, Goffin F, Bruchim I, Bischof P: Expression of matrix metalloproteinase-2 and mutant p53 is increased in hydatidiform mole as compared with normal placenta. Int. J. Gynecol. Cancer16,1679–1684 (2006).
  Medline CASGoogle Scholar
• 93  Vegh GL, Selcuk Tuncer Z, Fulop V, Genest DR, Mok SC, Berkowitz RS: Matrix metalloproteinases and their inhibitors in gestational trophoblastic diseases and normal placenta. Gynecol. Oncol.75,248–253 (1999).
  Medline CASGoogle Scholar